XiaoningSun

Associate

新加坡 + 65.6233.5500

联系：

Share

Xiaoning Sun represents financial institutions and sponsors/borrowers on a broad range of domestic and cross-border debt transactions, including club and syndicated loans; project, acquisition, and asset financings; and debt restructurings.

Prior to joining Jones Day in 2023, Xiaoning practiced at a top-tier international law firm in Singapore where she advised clients on a range of debt-related transactions, including project financing, asset financing, and capital call financing.

经验

  • Coronado Global Resources completes $400 million Senior Secured Notes offeringJones Day advised Coronado Global Resources Inc. (ASX: CRN) (“Coronado”), a global producer, marketer, and exporter of a full range of metallurgical coal products, in connection with an offering by one of its wholly-owned subsidiaries of US$400 million aggregate principal amount of 9.250% Senior Secured Notes due 2029 in a Rule 144A and Regulation S offering.
  • Five9 acquires AcqueonJones Day advised Five9, Inc. in its acquisition of Acqueon, a pioneering real-time revenue execution platform, realizing Five9's ambition to become the orchestration engine for every interaction across the entire customer journey, including marketing, e-commerce, sales and customer service through AI-driven, omnichannel proactive customer engagement.
  • Mayur Resources obtains US$155 million financing to complete Central Lime ProjectJones Day advised Mayur Resources Limited on the debt financing agreements with Appian Capital Advisory LLP and combined equity funding from Vision Blue Resources, a clean energy battery metals transition investment vehicle led by Sir Mick Davis, for a total of approximately US$155 million to complete the Central Lime Project.
  • Timken acquires Des-CaseJones Day advised The Timken Company in the acquisition of Des-Case Corp., a Nashville, Tenn.-based manufacturer of specialty filtration products for industrial lubricants.
  • Junshi grants exclusive rights to Dr. Reddy's for toripalimab cancer treatmentJones Day represented Shanghai Junshi Biosciences Co., Ltd. ("Junshi") in its grant of exclusive rights related to the development and commercialization of toripalimab, an anti-PD1 monoclonal antibody, to Dr. Reddy's Laboratories for the territory of Latin America, India, South Africa, and an option to expand the territory to include Australia and New Zealand and potential other countries.
    •

    July 2024 White Paper

    APAC ESG Update | Spring Quarter 2024

    2024年7月 白皮书

    亚太地区ESG最新动态 | 2024年春季

    February 2024 White Paper

    APAC ESG Update | Winter Quarter 2023–24

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice